We are pioneering approaches for building entirely synthetic genomes & for reprogramming the genetic code of living organisms for programmable polymer synthesis
As the market for GLP-1 agonists booms, The Observer UK explains how Constructive Bio has created a cleaner, more sustainable and efficient route to manufacturing the peptides. https://t.co/R7ArZVeJSV
Ready to explore non-canonical building blocks in proteins and peptides for cutting-edge results?
Our new explainer breaks it down in 90 seconds: from chaos to clarity 🚀
Boston-based serial entrepreneur & synthetic biology pioneer Rahul K Dhanda joins our BoD as NED. Rahul will deliver diverse expertise in platform development, strategic partnering, commercialisation & company-building, complementing the current team.
https://t.co/cqRw6nuNRW
Paul Wallace joins Constructive with 25+ years of international Business Development experience, commercialising innovative platforms and therapeutics. Together we will accelerate commercialisation of our ground-breaking genome reprogramming technology
https://t.co/cqRw6nuNRW
We're excited to welcome Dr Paul Wallace as our new Chief Business Officer and Rahul Dhanda as Non-Executive Director to our Board of Directors.
Link to full PR here: https://t.co/cqRw6nuNRW
#Appointments#CBO#NED#GenomeSynthesis
In a @TEDTalks Prof Jason Chin, the scientific brain behind @BioConstructiv, describes the rewriting of the genetic blueprint of cells to create a virus-resistant organism - the largest synthetic genome ever made!
Click here to listen:
https://t.co/OLvTSeZCyH
Constructive bio launches with $15m seed investment to re-engineer biology, creating new classes of enzymes, pharmaceuticals and biomaterials https://t.co/w9gGPMa9PF
"Re-engineering biology, Constructive Bio scores $15 million to make new class of enzymes"
Read more https://t.co/HWnYYj7QIL
#GlobalGoals#Sustainability#UNSDGs